O'Connell Joseph P 4
4 · Odonate Therapeutics, Inc. · Filed Feb 2, 2021
Insider Transaction Report
Form 4
O'Connell Joseph P
Chief Medical Officer
Transactions
- Award
Employee Stock Option (Right to Buy)
2021-01-29+82→ 82 totalExercise: $23.11Exp: 2031-01-29→ Common Stock (82 underlying) - Award
Common Stock
2021-01-29$19.64/sh+82$1,610→ 3,345 total
Footnotes (2)
- [F1]These shares were acquired on 01/29/2021 through the Odonate Therapeutics, Inc. 2017 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
- [F2]The stock options vest and become exercisable as follows: (i) 50% on the date of U.S. Food and Drug Administration ("FDA") approval of tesetaxel, Odonate's investigational product; (ii) 25% on the first anniversary of FDA approval of tesetaxel; and (iii) 25% on the second anniversary of FDA approval of tesetaxel. Vesting is subject to the Reporting Person's continued service to the Issuer through each vesting date.